175 related articles for article (PubMed ID: 37473593)
21. Spinal cord grey matter abnormalities are associated with secondary progression and physical disability in multiple sclerosis.
Kearney H; Schneider T; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Ciccarelli O; Miller DH
J Neurol Neurosurg Psychiatry; 2015 Jun; 86(6):608-14. PubMed ID: 25097217
[TBL] [Abstract][Full Text] [Related]
22. Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis: A post hoc analysis from the randomized, placebo-controlled AFFIRM trial.
Nakamura K; Sun Z; Hara-Cleaver C; Bodhinathan K; Avila RL
Mult Scler; 2024 May; 30(6):687-695. PubMed ID: 38469809
[TBL] [Abstract][Full Text] [Related]
23. Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
Tsagkas C; Huck-Horvath A; Cagol A; Haas T; Barakovic M; Amann M; Ruberte E; Melie-Garcia L; Weigel M; Pezold S; Schlaeger R; Kuhle J; Sprenger T; Kappos L; Bieri O; Cattin P; Granziera C; Parmar K
Mult Scler; 2023 May; 29(6):702-718. PubMed ID: 36550626
[TBL] [Abstract][Full Text] [Related]
24. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
[TBL] [Abstract][Full Text] [Related]
25. Cortical grey matter sodium accumulation is associated with disability and secondary progressive disease course in relapse-onset multiple sclerosis.
Brownlee WJ; Solanky B; Prados F; Yiannakas M; Da Mota P; Riemer F; Cardoso MJ; Ourselin S; Golay X; Gandini Wheeler-Kingshott C; Ciccarelli O
J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):755-760. PubMed ID: 30948625
[TBL] [Abstract][Full Text] [Related]
26. Neuroinflammatory component of gray matter pathology in multiple sclerosis.
Herranz E; Giannì C; Louapre C; Treaba CA; Govindarajan ST; Ouellette R; Loggia ML; Sloane JA; Madigan N; Izquierdo-Garcia D; Ward N; Mangeat G; Granberg T; Klawiter EC; Catana C; Hooker JM; Taylor N; Ionete C; Kinkel RP; Mainero C
Ann Neurol; 2016 Nov; 80(5):776-790. PubMed ID: 27686563
[TBL] [Abstract][Full Text] [Related]
27. MRI-Based Brain Volumetry at a Single Time Point Complements Clinical Evaluation of Patients With Multiple Sclerosis in an Outpatient Setting.
Raji A; Ostwaldt AC; Opfer R; Suppa P; Spies L; Winkler G
Front Neurol; 2018; 9():545. PubMed ID: 30140245
[No Abstract] [Full Text] [Related]
28. Clinical and MRI predictors of cognitive decline in patients with relapsing-remitting multiple sclerosis: A 2-year longitudinal study.
Dong X; Xu G; Wang J; Yin N; Meng N
Mult Scler Relat Disord; 2022 Sep; 65():103838. PubMed ID: 35749960
[TBL] [Abstract][Full Text] [Related]
29. Continuous diffuse brain atrophy independent of relapse as a hallmark of multiple sclerosis beginning from relapsing-remitting stage.
Akaishi T; Fujimori J; Yokote H; Nakashima I
Clin Neurol Neurosurg; 2024 Jul; 242():108342. PubMed ID: 38772279
[TBL] [Abstract][Full Text] [Related]
30. Effect of deep gray matter atrophy on information processing speed in early relapsing-remitting multiple sclerosis.
Naghavi S; Ashtari F; Adibi I; Shaygannejad V; Ramezani N; Pourmohammadi A; Davanian F; Karimi Z; Khaligh-Razavi SM; Sanayei M
Mult Scler Relat Disord; 2023 Mar; 71():104560. PubMed ID: 36806043
[TBL] [Abstract][Full Text] [Related]
31. The role of global and regional gray matter volume decrease in multiple sclerosis.
Grothe M; Lotze M; Langner S; Dressel A
J Neurol; 2016 Jun; 263(6):1137-45. PubMed ID: 27094570
[TBL] [Abstract][Full Text] [Related]
32. Association of Cortical Lesions With Regional Glutamate, GABA,
Madsen MA; Považan M; Wiggermann V; Lundell H; Blinkenberg M; Romme Christensen J; Sellebjerg F; Siebner HR
Neurology; 2024 Jul; 103(1):e209543. PubMed ID: 38870443
[TBL] [Abstract][Full Text] [Related]
33. Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
Haider L; Prados F; Chung K; Goodkin O; Kanber B; Sudre C; Yiannakas M; Samson RS; Mangesius S; Thompson AJ; Gandini Wheeler-Kingshott CAM; Ciccarelli O; Chard DT; Barkhof F
Brain; 2021 Jun; 144(5):1384-1395. PubMed ID: 33880511
[TBL] [Abstract][Full Text] [Related]
34. Relapsing-remitting and secondary-progressive multiple sclerosis patients differ in decoding others' emotions by their eyes.
Argento O; Spanò B; Serra L; Incerti CC; Bozzali M; Caltagirone C; Francia A; Fratino M; Nocentini U; Piacentini C; Quartuccio ME; Pisani V
Eur J Neurol; 2022 Feb; 29(2):505-514. PubMed ID: 34687120
[TBL] [Abstract][Full Text] [Related]
35. Exploring the effect of glatiramer acetate on cerebral gray matter atrophy in multiple sclerosis.
AbdelRazek MA; Tummala S; Khalid F; Tauhid S; Jalkh Y; Khalil S; Hurwitz S; Zurawski J; Bakshi R
J Neurol Sci; 2023 Jan; 444():120501. PubMed ID: 36481574
[TBL] [Abstract][Full Text] [Related]
36. Addition of quantitative MRI to the routine clinical care of patients with multiple sclerosis-Results from the MAGNON project.
Leussink VI; Jankovic M; Groth M; Schuh K; Sauerbeck IS; Hoffmann O
Brain Behav; 2024 Jun; 14(6):e3548. PubMed ID: 38841819
[TBL] [Abstract][Full Text] [Related]
37. Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.
Schweser F; Raffaini Duarte Martins AL; Hagemeier J; Lin F; Hanspach J; Weinstock-Guttman B; Hametner S; Bergsland N; Dwyer MG; Zivadinov R
Neuroimage; 2018 Feb; 167():438-452. PubMed ID: 29097315
[TBL] [Abstract][Full Text] [Related]
38. Measures of Thalamic Integrity are Associated with Cognitive Functioning in Fingolimod-treated Multiple Sclerosis Patients.
Conway DS; Planchon SM; Oh SH; Nakamura K; Thompson NR; Sakaie K; Ontaneda D
Mult Scler Relat Disord; 2021 Jan; 47():102635. PubMed ID: 33260053
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal changes of deep gray matter shape in multiple sclerosis.
Tsagkas C; Geiter E; Gaetano L; Naegelin Y; Amann M; Parmar K; Papadopoulou A; Wuerfel J; Kappos L; Sprenger T; Granziera C; Mallar Chakravarty M; Magon S
Neuroimage Clin; 2022; 35():103137. PubMed ID: 36002960
[TBL] [Abstract][Full Text] [Related]
40. Pattern of thalamic nuclei atrophy in early relapse-onset multiple sclerosis.
Levy S; Sandry J; Beck ES; Brandstadter R; Katz Sand I; Sumowski JF
Mult Scler Relat Disord; 2022 Nov; 67():104083. PubMed ID: 35940020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
